(August 23, 2018, 9:54 AM EDT) -- CHICAGO — The Seventh Circuit U.S. Court of Appeals on Aug. 22 reversed a $3 million generic Paxil suicide verdict, finding that the Food and Drug Administration repeatedly rejected requests by brand-name drug maker GlaxoSmithKline LLC (GSK) to add a warning about the risk of adult suicide to the label of the brand-name and generic drug (Wendy B. Dolin, et al. v. GlaxoSmithKline LLC, et al., No. 17-3030, 7th Cir., 2018 U.S. App. LEXIS 23598)....